Francois Guilhot

Francois Guilhot

UNVERIFIED PROFILE

Are you Francois Guilhot?   Register this Author

Register author
Francois Guilhot

Francois Guilhot

Publications by authors named "Francois Guilhot"

Are you Francois Guilhot?   Register this Author

100Publications

3318Reads

32Profile Views

The -7 chromosomal abnormalities with signs of myelodysplasia in chronic myeloid leukemia as a major red signal.

Haematologica 2019 Jun;104(6):1096-1098

Inserm CIC 1402, University Hospital of Poitiers, CHU de Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.217034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545827PMC
June 2019

Ponatinib and platelets a conflict in CML.

Blood 2019 Apr;133(14):1520-1521

INSERM Clinical Investigation Centre 1402.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2019-02-900472DOI Listing
April 2019

Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells.

Biochem Biophys Res Commun 2018 04 17;498(4):715-722. Epub 2018 Mar 17.

INSERM U935, Poitiers, Université de Poitiers, France; INSERM U935 Université Paris Sud & Service d'Hématologie, Institur Federatif d'Hématologie IFHIPS, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2018.03.023DOI Listing
April 2018

Age-related health care disparities in multiple myeloma.

Hematol Oncol 2018 Feb 21;36(1):224-231. Epub 2017 Apr 21.

INSERM CIC 1402, CHU, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2422DOI Listing
February 2018

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.

Health Qual Life Outcomes 2017 Oct 18;15(1):204. Epub 2017 Oct 18.

Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12955-017-0788-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648464PMC
October 2017

Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches.

BioDrugs 2017 Jun;31(3):143-149

INSERM CIC 1402, CHU de Poitiers, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-017-0225-6DOI Listing
June 2017

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

N Engl J Med 2017 03;376(10):917-927

From Abteilung Hämatologie-Onkologie, Universitätsklinikum Jena, Jena, Germany (A.H.); the Department of Medicine, University of Chicago, Chicago (R.A.L.); INSERM Centre d'Investigation Clinique 1402, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (F.G.); Fred Hutchinson Cancer Research Center, Seattle (J.P.R.); Centre for Cancer Biology, SA Pathology, University of South Australia and University of Adelaide (S.B.), and the South Australian Health and Medical Research Institute and University of Adelaide (T.P.H.), Adelaide, SA, Australia; University of Bologna, Bologna, Italy (M.B.); the University of Utah Huntsman Cancer Institute, Salt Lake City (M.W.D.); the Hematology Department, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (F.C.); Novartis, Basel, Switzerland (S.F., C.-E.O., H.D.M.); M.D. Anderson Cancer Center, Houston (H.K.); the University of Newcastle, Newcastle, United Kingdom (S.G.O.); and Knight Cancer Institute, Oregon Health and Science University and Howard Hughes Medical Institute, Portland (B.J.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901965PMC
March 2017

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

J Clin Oncol 2017 Jan 31;35(3):298-305. Epub 2016 Oct 31.

Gabriel Etienne and François-Xavier Mahon, Institut Bergonié, Bordeaux; Joëlle Guilhot and François Guilhot, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers; Delphine Rea, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP); Bruno Varet, Hôpital Necker, AP-HP et Université Paris Descartes, Paris; Françoise Rigal-Huguet, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse; Franck Nicolini, Centre Hospitalier Lyon Sud, Pierre Bénite; Aude Charbonnier, Institut Paoli Calmette, Marseille; Agnès Guerci-Bresler, CHU Brabois Vandoeuvre, Nancy; Laurence Legros, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice; Martine Gardembas, CHU d'Angers, Angers; Viviane Dubruille, CHU Hôtel-Dieu, Nantes; Michel Tulliez, Hôpital Henri Mondor, Créteil; Marie-Pierre Noel, Hôpital Claude Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille; Jean-Christophe Ianotto, CHU Morvan, Brest; Bruno Villemagne, Centre Hospitalier Départemental La Roche-Sur-Yon, La Roche-Sur-Yon; Martin Carré, Hôpital Albert Michallon, CHU de Grenoble, Grenoble; Philippe Rousselot, Hôpital André Mignot, Le Chesnay; and François-Xavier Mahon, CHU de Bordeaux, INSERM U1218, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2914DOI Listing
January 2017

Beyond tyrosine kinase inhibitors: Combinations and other agents.

Best Pract Res Clin Haematol 2016 09 20;29(3):271-283. Epub 2016 Oct 20.

Inserm CIC 1402, CHU de Poitiers, Poitiers, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2016.10.017DOI Listing
September 2016

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

J Natl Cancer Inst 2016 Jul 4;108(7). Epub 2016 Mar 4.

Affiliations of authors:Department of Health Policy and Management, Johns Hopkins University , Baltimore, MD (WVP); Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL; Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center , and Cecil G. Sheps Center for Health Services Research, University of North Carolina , Chapel Hill, NC (SBD); Department of Haematology, Hammersmith Hospital, Imperial College , London , UK (JFA); Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany; Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna , Bologna , Italy ; Department of Haematology and Oncology, University Hospital , Jena , Germany (EE); INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG); Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM); Department of Internal Medicine, Hematology and Oncology, University Hospital Brno , Brno , Czech Republic (JM); Department of Hematology and Oncology, University Hospital Leipzig , Leipzig , Germany (DN); Barbara Ann Karmanos Cancer Institute, Wayne State University , Detroit, MI (CAS); Department of Medicine, Weill Cornell Medical Center , New York, NY (RTS); Uppsala University , Uppsala , Sweden (BS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948567PMC
July 2016

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2016 06 29;16(6):341-349.e1. Epub 2016 Mar 29.

Department of Oncology, Hematology, and Cell Therapy, Centre Hospitalier Universitaire de Poitiers, Clinical Investigation Center, Inserm 0802, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.03.004DOI Listing
June 2016

Cytogenetics in CML: more important than you think.

Blood 2016 06;127(22):2661-2

INSERM CLINICAL INVESTIGATION CENTRE 1402.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-04-708206DOI Listing
June 2016

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Blood 2016 Feb 24;127(6):703-12. Epub 2015 Nov 24.

Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-08-660977DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760131PMC
February 2016

The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.

Exp Hematol 2015 Sep 26;43(9):775-80. Epub 2015 Jun 26.

Institut national U935 de la santé et de la recherche médicale, Université de Poitiers, Poitiers, France; Institut national U935 de la santé et de la recherche médicale, Hôpitaux Universitaires Paris Sud Bicêtre, Université Paris-Sud 11, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2015.04.013DOI Listing
September 2015

Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules.

Cancer 2015 Feb 24;121(4):490-7. Epub 2014 Oct 24.

INSERM Clinical Investigation Center 1402, Poitiers University, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29053DOI Listing
February 2015

Imatinib treatment and Aβ42 in humans.

Alzheimers Dement 2014 Oct 10;10(5 Suppl):S374-80. Epub 2013 Dec 10.

Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jalz.2013.08.283DOI Listing
October 2014

BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients.

Cancer Res 2014 May 27;74(10):2669-76. Epub 2014 Mar 27.

Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2797DOI Listing
May 2014

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

J Clin Oncol 2014 Feb 9;32(5):424-30. Epub 2013 Dec 9.

Philippe Rousselot, Hôpital Mignot, Université Versailles Saint-Quentin-en-Yvelines, Versailles; Aude Charbonnier, Institut Paoli Calmette, Marseille; Pascale Cony-Makhoul, Hôpital d'Annecy, Pringy; Philippe Agape, Hôpital Felix Guyon-Centre Hospitalier Universitaire en France (CHU) de la Réunion, La Réunion; Franck E. Nicolini, Centre Hospitalier Lyon Sud, Pierre-Bénite; Bruno Varet, Hôpital Necker, Assistance Publique-Hopitaux de Paris (AP-HP) et Université Paris Descartes; Delphine Réa and Jean Michel Cayuela, Hôpital Saint-Louis, AP-HP, Paris; Martine Gardembas, CHU d'Angers, Angers; Gabriel Etienne and Josy Reiffers, Institut Bergonié; François-Xavier Mahon, Hôpital Haut-Levèque et Université Bordeaux Ségalen, Bordeaux; Lydia Roy, Joëlle Guilhot, and François Guilhot, Institut National de la Santé et de la Recherche Médicale (INSERM) Centres d'Investigation Clinique CHU de Poitiers, Poitiers; Martine Escoffre-Barbe, Centre Hospitalier Pontchaillou, Rennes; Agnès Guerci-Bresler, CHU Brabois Vandoeuvre, Nancy; Michel Tulliez, Hôpital Henri Mondor, AP-HP, Créteil; Stéphane Prost, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Institute of Emerging Diseases and Innovative Therapies, Fontenay-aux-Roses; Marc Spentchian, Hôpital Mignot, Le Chesnay; and Jean Claude Chomel and Ali Turhan, INSERM U935, Université Poitiers et Paris Sud, Le Kremlin Bicêtre, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.5797DOI Listing
February 2014

Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas.

Eur J Radiol 2013 Nov 9;82(11):2011-7. Epub 2013 Aug 9.

Department of Radiology, CHU de Poitiers, rue de la milétrie, 86000 Poitiers, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2013.05.042DOI Listing
November 2013

An enzyme-responsive system programmed for the double release of bioactive molecules through an intracellular chemical amplification process.

Org Biomol Chem 2013 Nov;11(41):7129-33

Université de Poitiers, UMR-CNRS 7285, Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP), Groupe « Systèmes Moléculaires Programmés », 4 rue Michel Brunet, BP 633, 86022 Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c3ob41536hDOI Listing
November 2013

Failure of fluorodeoxyglucose positron emission tomography to detect the high-grade transformation of nodular lymphocyte predominant Hodgkin's lymphoma.

Acta Haematol 2013 11;129(4):229-31. Epub 2013 Jan 11.

Department of Onco-Hematology and Cellular Therapy, CHU Poitiers, FR-86021 Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000345261DOI Listing
August 2013

Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.

Leuk Res 2012 Jul 23;36(7):817-25. Epub 2012 Feb 23.

Patient Reported Outcomes, Adelphi Values, Cheshire, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.01.021DOI Listing
July 2012

Curing chronic myeloid leukemia.

Curr Hematol Malig Rep 2012 Jun;7(2):103-8

Service des Maladies du Sang et EA3518, Hôpital Saint-Louis, AP-HP, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-012-0117-2DOI Listing
June 2012

Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin.

J Med Chem 2012 May 30;55(9):4516-20. Epub 2012 Apr 30.

Institut de Chimie des Milieux et des Matériaux de Poitiers, IC2MP, Université de Poitiers, UMR-CNRS 7285, 4 Rue Michel Brunet, 86022 Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm300348rDOI Listing
May 2012

Current treatment strategies in chronic myeloid leukemia.

Curr Opin Hematol 2012 Mar;19(2):102-9

Centre Investigation Clinique Inserm CIC 0802, CHU de Poitiers, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0b013e32834ff610DOI Listing
March 2012

Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response.

Blood 2011 Nov 29;118(19):5096-8. Epub 2011 Aug 29.

Department of Onco-Hematology, Centre Hospitalier Universitaire de Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-03-335588DOI Listing
November 2011

Ph: not bad at all.

Blood 2011 Jun;117(25):6741-2

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-04-346650DOI Listing
June 2011

Predicting response in CML.

Blood 2011 Feb;117(6):1773-4

CIC 802 INSERM.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-11-317123DOI Listing
February 2011

Endoscopic diagnosis of childhood Burkitt's lymphoma of the colon.

J Clin Oncol 2010 Aug 20;28(22):e374-5. Epub 2010 Apr 20.

Department of Hematology, University Hospital, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.25.6990DOI Listing
August 2010

Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.

Haematologica 2010 Aug 11;95(8):1325-33. Epub 2010 May 11.

Gene and Stem Cell Therapy Program, Centenary Institute, Locked Bag No 6, Newtown, NSW 2042, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2009.020636DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913081PMC
August 2010

Hematology: dasatinib regimens for patients with chronic myeloid leukemia.

Nat Rev Clin Oncol 2009 Dec;6(12):680-2

Department of Oncology, Hematology, and Cell Therapy, Bone Marrow Transplant Unit, Centre Hospitalier Universitaire de Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2009.160DOI Listing
December 2009

Interferon in chronic myeloid leukaemia: past and future.

Best Pract Res Clin Haematol 2009 Sep;22(3):315-29

INSERM CIC 0802 and Department of Oncology-Haematology and Cell Therapy, CHU de Poitiers, 2 Rue de la Milétrie, 86021 POITIERS CEDEX, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2009.10.005DOI Listing
September 2009

Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.

Pediatr Blood Cancer 2009 Jul;52(7):891-2

Service d'Oncologie Hématologique et de Thérapie Cellulaire, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.21938DOI Listing
July 2009

Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.

Cancer 2009 Apr;115(7):1381-94

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.24155DOI Listing
April 2009

Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia.

Leuk Lymphoma 2008 May;49(5):984-8

Service d'Hématologie et Oncologie Biologique - EA 3805, CHU de Poitiers, Université de Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190801942360DOI Listing
May 2008

Immunotherapeutic approaches in chronic myelogenous leukemia.

Leuk Lymphoma 2008 Apr;49(4):629-34

Department of Oncology-Haematology and Cell Therapy, EA 3805 and Clinical Research Centre, CHU de Poitiers, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190801927510DOI Listing
April 2008

Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.

Semin Oncol 2008 Feb;35(1 Suppl 1):S1-17; quiz S18-20

Professor of Medicine, and Chief, Division of Hematology and Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2007.12.002DOI Listing
February 2008